205 related articles for article (PubMed ID: 20227784)
41. Vinorelbine-gemcitabine in advanced non-small-cell lung cancer (NSCLC): an AASLC phase II trial. Austrian Association for the Study of Lung Cancer.
Krajnik G; Mohn-Staudner A; Thaler J; Greil R; Schmeikal S; Marhold F; Deutsch J; Preiss P; Malayeri R; Schäfer-Prokop C; Wein W; Huber H; Pirker R
Ann Oncol; 2000 Aug; 11(8):993-8. PubMed ID: 11038036
[TBL] [Abstract][Full Text] [Related]
42. Gemcitabine, ifosfamide and vinorelbine in advanced non-small cell lung cancer: a phase II study.
Recchia F; Lombardo M; De Filippis S; Rosselli M; Rea S
Anticancer Res; 2002; 22(2B):1321-8. PubMed ID: 12168945
[TBL] [Abstract][Full Text] [Related]
43. Gemcitabine, Ifosfamide and Navelbine (GIN): activity and safety of a non-platinum-based triplet in advanced non-small-cell lung cancer (NSCLC).
Baldini E; Ardizzoni A; Prochilo T; Cafferata MA; Boni L; Tibaldi C; Neumaier C; Conte PF; Rosso R;
Br J Cancer; 2001 Nov; 85(10):1452-5. PubMed ID: 11720427
[TBL] [Abstract][Full Text] [Related]
44. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group.
Comella P; Frasci G; Panza N; Manzione L; De Cataldis G; Cioffi R; Maiorino L; Micillo E; Lorusso V; Di Rienzo G; Filippelli G; Lamberti A; Natale M; Bilancia D; Nicolella G; Di Nota A; Comella G
J Clin Oncol; 2000 Apr; 18(7):1451-7. PubMed ID: 10735892
[TBL] [Abstract][Full Text] [Related]
45. Options in advanced non-small cell lung cancer: a review and report on a phase II study of vinorelbine plus gemcitabine.
Lilenbaum R
Oncologist; 2001; 6 Suppl 1():16-9. PubMed ID: 11182000
[TBL] [Abstract][Full Text] [Related]
46. Phase II study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in patients with inoperable stage III non-small-cell lung cancer.
Lee DH; Han JY; Cho KH; Pyo HR; Kim HY; Yoon SJ; Lee JS
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1037-44. PubMed ID: 16024178
[TBL] [Abstract][Full Text] [Related]
47. Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer.
Beretta GD; Michetti G; Belometti MO; Gritti G; Quadri A; Poletti P; Labianca R
Br J Cancer; 2000 Sep; 83(5):573-6. PubMed ID: 10944594
[TBL] [Abstract][Full Text] [Related]
48. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.
Quoix E; Zalcman G; Oster JP; Westeel V; Pichon E; Lavolé A; Dauba J; Debieuvre D; Souquet PJ; Bigay-Game L; Dansin E; Poudenx M; Molinier O; Vaylet F; Moro-Sibilot D; Herman D; Bennouna J; Tredaniel J; Ducoloné A; Lebitasy MP; Baudrin L; Laporte S; Milleron B;
Lancet; 2011 Sep; 378(9796):1079-88. PubMed ID: 21831418
[TBL] [Abstract][Full Text] [Related]
49. Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer.
Han JY; Lee DH; Song JE; Lee SY; Kim HY; Kim HT; Lee JS
Cancer; 2008 Jul; 113(2):388-95. PubMed ID: 18484595
[TBL] [Abstract][Full Text] [Related]
50. [Efficacy of gemcitabine and vinorelbine in first-line treatment with advanced non-small cell lung cancer: a multicentre retrospective study].
Yu Y; Zhang L; Ren Z; Zhao J; Li Z; Lu S
Zhongguo Fei Ai Za Zhi; 2012 May; 15(5):281-6. PubMed ID: 22613334
[TBL] [Abstract][Full Text] [Related]
51. Platinum doublets as first-line treatment for elderly patients with advanced non-small cell lung cancer.
Piacentini P; Greco F; Mercanti A; Trolese AR; Durante E; Moratello G; Tognetto M; Furini L; Giuliani J; Bonetti A
Tumori; 2013; 99(6):650-5. PubMed ID: 24503786
[TBL] [Abstract][Full Text] [Related]
52. Gemcitabine and vinorelbine as second-line therapy for non-small cell lung cancer after treatment with paclitaxel plus platinum.
Park YH; Lee JC; Kim CH; Ryoo BY; Kim HT
Jpn J Clin Oncol; 2004 May; 34(5):245-9. PubMed ID: 15231858
[TBL] [Abstract][Full Text] [Related]
53. A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) non-small-cell lung cancer patients aged 80 or older.
Chen YM; Perng RP; Chen MC; Tsai CM; Ming-Liu J; Whang-Peng J
Lung Cancer; 2003 May; 40(2):221-6. PubMed ID: 12711125
[TBL] [Abstract][Full Text] [Related]
54. Gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: a phase II study.
Lilenbaum R; Cano R; Schwartz M; Siegel L; Lutzky J; Lewis M; Krill E; Barreras L; Davila E
Cancer; 2000 Feb; 88(3):557-62. PubMed ID: 10649247
[TBL] [Abstract][Full Text] [Related]
55. Gemcitabine plus vinorelbine for the treatment of advanced non-small cell lung cancer.
Barón F; Cueva J; Graña B; Curiel T; León L; Vázquez F; Candamio S; López R
Eur J Cancer; 2001 Jul; 37(11):1381-4. PubMed ID: 11435068
[TBL] [Abstract][Full Text] [Related]
56. Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study.
Pallis AG; Syrigos K; Kotsakis A; Karachaliou N; Polyzos A; Chandrinos V; Varthalitis I; Christophyllakis C; Ardavanis A; Vamvakas L; Vardakis N; Saridaki Z; Samonis G; Giassas S; Georgoulias V; Agelaki S
Clin Lung Cancer; 2011 Mar; 12(2):100-5. PubMed ID: 21550556
[TBL] [Abstract][Full Text] [Related]
57. Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG).
Kotsakis A; Kentepozidis N; Emmanouilidis Ch; Polyzos A; Agelidou A; Vaslamatzis M; Chandrinos V; Agelaki S; Vamvakas L; Kalbakis K; Katsaounis P; Stoltidis D; Nintos G; Hatzidaki D; Vetsika EK; Mavroudis D; Georgoulias V
Lung Cancer; 2015 Apr; 88(1):57-62. PubMed ID: 25662596
[TBL] [Abstract][Full Text] [Related]
58. Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
Li X; Shao M; Wang S; Zhao X; Chen H; Qian J; Song X; Wang J; Jin L; Wu J; Li Q; Bai C; Han B; Gao Z; Lu D
Tumour Biol; 2014 Nov; 35(11):11159-70. PubMed ID: 25104092
[TBL] [Abstract][Full Text] [Related]
59. Combination chemotherapy of gemcitabine and vinorelbine for patients in stage IIIB-IV non-small cell lung cancer: a phase II study of the West Japan Thoracic Oncology Group (WJTOG) 9908.
Katakami N; Sugiura T; Nogami T; Yamamoto H; Negoro S; Nakano T; Okamoto N; Takada Y; Kodama K; Ariyoshi Y
Lung Cancer; 2004 Jan; 43(1):93-100. PubMed ID: 14698543
[TBL] [Abstract][Full Text] [Related]
60. Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer: a phase II trial.
Laack E; Mende T; Benk J; Chemaissani A; Scholtze J; Lorenz C; Niestroy A; Dalhoff K; Müller T; Walter T; Dürk H; Edler L; Hossfeld DK
Eur J Cancer; 2001 Mar; 37(5):583-90. PubMed ID: 11290433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
